Rezolute, Inc. (NASDAQ:RZLT – Free Report) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Rezolute in a research report issued to clients and investors on Monday, September 18th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.38) EPS.
A number of other research firms also recently issued reports on RZLT. Cantor Fitzgerald reissued an “overweight” rating and set a $5.00 price target on shares of Rezolute in a research report on Tuesday. JMP Securities reissued a “market outperform” rating and set a $8.00 price target on shares of Rezolute in a research report on Friday, September 15th.
Rezolute Trading Down 3.4 %
RZLT stock opened at $1.44 on Tuesday. The stock has a 50-day moving average price of $1.62 and a two-hundred day moving average price of $1.92. Rezolute has a 12-month low of $1.34 and a 12-month high of $3.20. The company has a market cap of $53.03 million, a PE ratio of -1.44 and a beta of 2.16.
Rezolute (NASDAQ:RZLT – Get Free Report) last posted its quarterly earnings results on Thursday, September 14th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.11.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of RZLT. Millennium Management LLC acquired a new position in shares of Rezolute during the fourth quarter worth about $32,000. FMR LLC acquired a new position in shares of Rezolute during the first quarter worth about $39,000. Renaissance Technologies LLC acquired a new position in shares of Rezolute during the second quarter worth about $58,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Rezolute in the fourth quarter worth about $67,000. Finally, State Street Corp acquired a new position in shares of Rezolute in the first quarter worth about $69,000. Institutional investors and hedge funds own 65.79% of the company’s stock.
Rezolute Company Profile
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Featured Articles
- Five stocks we like better than Rezolute
- Market Cap Calculator: How to Calculate Market Cap
- Hold-It-Forever AutoZone Pulls into Buy Zone
- How to Read Stock Charts for Beginners
- Virtual Riches: 3 Stocks Leading the VR Revolution
- How to Invest in Energy
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.
